SYNLOGIC

Synlogic is a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases in need of new treatment options. The Company focuses on rare metabolic diseases, with its lead program, labafenogene marselecobac (SYNB1934), currently being studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for classical homocystinuria (HCU). Both PKU and HCU are caused by inborn errors of metabolism, and present significant need for innovation due to limitations of today's medical treatment options... Synlogic is the leading company advancing therapeutics based on synthetic biology, working at the intersection of biology and engineering to treat disease.

Primary location: Cambridge United States